SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Marinus Pharmaceuticals, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - January 2, 2025) - Rigrodsky Law, P.A. is investigating Marinus Pharmaceuticals, Inc. ("Marinus") (NASDAQ GM: MRNS) regarding possible breaches of fiduciary duties and other violations of law related to Marinus' agreement to be acquired by Immedica Pharma AB. Under the terms of the agreement, Marinus shareholders will receive $0.55 per share in cash.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-marinus-pharmaceuticals-inc.

To contact Seth D. Rigrodsky or Gina M. Serra cost free, call (302) 295-5310 or email [email protected].

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235913

You May Also Be Interested In

• Irenic Capital opposes Independence Realty's Centerspace deal - Bloomberg
• Boston Scientific wins $135.7M military cardiovascular supply contract
• Uniserve Reports Results for Fiscal Year Ended May 31, 2026